344338-13-2

Upstream product

• 4124-41-8 p-toluenesulfonylanhydride 
• 4934-99-0 methylester of 3-hydroxycyclobutane-1-carboxylic acid 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 695-95-4 methyl 3-oxocyclobutanecarboxylate 
• 54166-15-3 diethyl 3-(benzyloxy)cyclobutane-1,1-dicarboxylate 
• 4958-02-5 3-(benzyloxy)cyclobutane-1-carboxylic acid 
• 84182-46-7 3-(benzyloxy)cyclobutane-1,1-dicarboxylic acid 
• 4934-98-9 methylester of 3-benzyloxycyclobutane-1-carboxylic acid 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 847690-63-5 methyl 3-(4-{5-[(pyridin-3-ylmethylamino)carbonyl]-1H-benzimidazol-1-yl}phenoxy)cyclobutanecarboxylate 
• 84182-59-2 hydrochloride of cis-3-aminocyclobutane-1-carboxylic acid 
• 74307-75-8 (1r,3r)-3-aminocyclobutane-1-carboxylic acid 
• 344348-50-1 amide of 3-p-toluenesulfonyloxycyclobutane-1-carboxylic acid 

Relevant academic research and scientific papers

COMPOUND SERVING AS IRAK INHIBITOR

The present disclosure relates a compound as an IRAK inhibitor. Specifically, the present disclosure provides a compound of formula I, or a cis-trans isomer, an optical isomer, a racemate, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative thereof, a hydrate or a solvate thereof. The compounds disclosed herein have potent inhibitory effects on IRAK and thus have therapeutic effect on IRAK-related diseases.

5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS

Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS

The present invention provides compounds of Formula (I): useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

Provided herein are dihydropyrimidine derivatives which are useful in the treatment of HBV infection or HBV-induced diseases, as well as pharmaceutical or medical applications thereof.

Synthesis of Electron-Deficient Heteroaromatic 1,3-Substituted Cyclobutyls via Zinc Insertion/Negishi Coupling Sequence under Batch and Automated Flow Conditions

Synthesis of 1,3-substituted cyclobutyls enabled by zinc insertion into functionalized iodocyclobutyl derivatives followed by Negishi coupling with halo-heteroaromatics is reported. Two distinct sets of conditions were developed; the first involved a two-step batch protocol using activated Rieke zinc, and the second involved a multistep continuous flow process. Both methods showed complementarity and allowed for rapid access to these medicinally relevant motifs, the possibility of scaling up, and automation for library synthesis.

SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1) - mediated diseases or disorders, Formula (I), wherein R1, R2, R3, R4, and R5 are as defined herein.

N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS

Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.